| Target Price | €5.10 |
| Price | €1.09 |
| Potential |
367.89%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Vivoryon Therapeutics 2027 .
The average Vivoryon Therapeutics target price is €5.10.
This is
367.89%
register free of charge
€7.19
559.86%
register free of charge
€5.05
363.30%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Vivoryon Therapeutics to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vivoryon Therapeutics stock has an average upside potential 2027 of
367.89%
register free of charge
|
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Jun 11 2026 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Jun 10 2026 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Jan 05 2026 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Dec 08 2025 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Dec 05 2025 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Jun 11 2026 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Jun 10 2026 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Jan 05 2026 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Dec 08 2025 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Dec 05 2025 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Sep 05 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Sep 04 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


